Ascentage Pharma Group International Announces Regulatory Review for Lisaftoclax in China Following New Drug Application Submission
I'm PortAI, I can summarize articles.
Ascentage Pharma Group International has announced the regulatory review of its new drug application for lisaftoclax in China. This Bcl-2 inhibitor shows promise in treating difficult myeloid malignancies, with potential approval making it the second Bcl-2 inhibitor globally. The submission highlights Ascentage's dedication to innovative therapies for patients with limited options.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments